|
1
|
Gaitskell K, Martinek I, Bryant A, Kehoe
S, Nicum S and Morrison J: Angiogenesis inhibitors for the
treatment of ovarian cancer. Cochrane Database Syst Rev.
9:CD0079302011.PubMed/NCBI
|
|
2
|
Banerjee S and Kaye S: The role of
targeted therapy in ovarian cancer. Eur J Cancer. 47(Suppl 3):
S116–S130. 2011. View Article : Google Scholar
|
|
3
|
Oei AL, Sweep FC, Thomas CM, Boerman OC
and Massuger LF: The use of monoclonal antibodies for the treatment
of epithelial ovarian cancer (Review). Int J Oncol. 32:1145–1157.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Reichert JM: Antibody-based therapeutics
to watch in 2011. MAbs. 3:76–99. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Itamochi H: Targeted therapies in
epithelial ovarian cancer: molecular mechanisms of action. World J
Biol Chem. 1:209–220. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Richardson DL, Backes FJ, Seamon LG, et
al: Combination gemcitabine, platinum, and bevacizumab for the
treatment of recurrent ovarian cancer. Gynecol Oncol. 111:461–466.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jurado JM, Sánchez A, Pajares B, Pérez E,
Alonso L and Alba E: Combined oral cyclophosphamide and bevacizumab
in heavily pre-treated ovarian cancer. Clin Transl Oncol.
10:583–586. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Perren TJ, Swart AM, Pfisterer J, et al: A
phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med.
365:2484–2496. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Köhne CH: How to integrate molecular
targeted agents in the continuum of care. Ann Oncol. 21(Suppl 7):
vii134–vii139. 2010.PubMed/NCBI
|
|
10
|
Moroney JW, Sood AK and Coleman RL:
Aflibercept in epithelial ovarian carcinoma. Future Oncol.
5:591–600. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Teng LS, Jin KT, He KF, Zhang J, Wang HH
and Cao J: Clinical applications of VEGF-trap (aflibercept) in
cancer treatment. J Chin Med Assoc. 73:449–456. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Colombo N, Mangili G, Mammoliti S, et al:
A phase II study of aflibercept in patients with advanced
epithelial ovarian cancer and symptomatic malignant ascites.
Gynecol Oncol. 125:42–47. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Coleman RL, Duska LR, Ramirez PT, et al:
Phase 1–2 study of docetaxel plus aflibercept in patients with
recurrent ovarian, primary peritoneal, or fallopian tube cancer.
Lancet Oncol. 12:1109–1117. 2011.
|
|
14
|
Neal J and Wakelee H: AMG-386, a selective
angiopoietin-1/-2-neutralizing peptibody for the potential
treatment of cancer. Curr Opin Mol Ther. 12:487–495.
2010.PubMed/NCBI
|
|
15
|
Karlan BY, Oza AM, Richardson GE, et al:
Randomized, double-blind, placebo-controlled phase II Study of AMG
386 combined with weekly paclitaxel in patients with recurrent
ovarian cancer. J Clin Oncol. 30:362–371. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yarom N and Jonker DJ: The role of the
epidermal growth factor receptor in the mechanism and treatment of
colorectal cancer. Discov Med. 11:95–105. 2011.PubMed/NCBI
|
|
17
|
Steffensen KD, Waldstrøm M, Jeppesen U,
Jakobsen E, Brandslund I and Jakobsen A: The prognostic importance
of cyclooxygenase 2 and HER2 expression in epithelial ovarian
cancer. Int J Gynecol Cancer. 17:798–807. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Farley J, Fuchiuji S, Darcy KM, et al:
Associations between ERBB2 amplification and progression-free
survival and overall survival in advanced stage,
suboptimally-resected epithelial ovarian cancers: a Gynecologic
Oncology Group Study. Gynecol Oncol. 113:341–347. 2009. View Article : Google Scholar
|
|
19
|
Tang L and Zhao X: Polyclonal antitumor
immunoglobulin may play a role in ovarian cancer adjuvant therapy.
Med Hypotheses. 76:530–532. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Makhija S, Amler LC, Glenn D, et al:
Clinical activity of gemcitabine plus pertuzumab in
platinum-resistant ovarian cancer, fallopian tube cancer, or
primary peritoneal cancer. J Clin Oncol. 28:1215–1223. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Langdon SP, Faratian D, Nagumo Y, Mullen P
and Harrison DJ: Pertuzumab for the treatment of ovarian cancer.
Expert Opin Biol Ther. 10:1113–1120. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sheng Q, Liu X, Fleming E, et al: An
activated ErbB3/NRG1 autocrine loop supports in vivo proliferation
in ovarian cancer cells. Cancer Cell. 17:298–310. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Konner JA, Bell-McGuinn KM, Sabbatini P,
et al: Farletuzumab, a humanized monoclonal antibody against folate
receptor alpha, in epithelial ovarian cancer: a phase I study. Clin
Cancer Res. 16:5288–5295. 2010. View Article : Google Scholar
|
|
24
|
Berek J, Taylor P, McGuire W, Smith LM,
Schultes B and Nicodemus CF: Oregovomab maintenance
monoimmunotherapy does not improve outcomes in advanced ovarian
cancer. J Clin Oncol. 27:418–425. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sabbatini P, Dupont J, Aghajanian C, et
al: Phase I study of abagovomab in patients with epithelial
ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer
Res. 12:5503–5510. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Grisham RN, Berek J, Pfisterer J and
Sabbatini P: Abagovomab: an anti-idiotypic CA-125 targeted
immunotherapeutic agent for ovarian cancer. Immunotherapy.
3:153–162. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ruf P and Lindhofer H: Induction of a
long-lasting antitumor immunity by a trifunctional bispecific
antibody. Blood. 98:2526–2534. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Baumann K, Pfisterer J, Wimberger P, et
al: Intraperitoneal treatment with the trifunctional bispecific
antibody Catumaxomab in patients with platinum-resistant epithelial
ovarian cancer: a phase IIa study of the AGO Study Group. Gynecol
Oncol. 123:27–32. 2011. View Article : Google Scholar
|
|
29
|
Bell-McGuinn KM, Matthews CM, Ho SN, et
al: A phase II, single-arm study of the anti-α5β1 integrin antibody
volociximab as monotherapy in patients with platinum-resistant
advanced epithelial ovarian or primary peritoneal cancer. Gynecol
Oncol. 121:273–279. 2011.
|
|
30
|
Matei D, Sill MW, Lankes HA, et al:
Activity of sorafenib in recurrent ovarian cancer and primary
peritoneal carcinomatosis: a gynecologic oncology group trial. J
Clin Oncol. 29:69–75. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bodnar L, Górnas M and Szczylik C:
Sorafenib as a third line therapy in patients with epithelial
ovarian cancer or primary peritoneal cancer: a phase II study.
Gynecol Oncol. 123:33–36. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ramasubbaiah R, Perkins SM, Schilder J, et
al: Sorafenib in combination with weekly topotecan in recurrent
ovarian cancer, a phase I/II study of the Hoosier Oncology Group.
Gynecol Oncol. 123:499–504. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Welch SA, Hirte HW, Elit L, et al:
Sorafenib in combination with gemcitabine in recurrent epithelial
ovarian cancer: a study of the Princess Margaret Hospital Phase II
Consortium. Int J Gynecol Cancer. 20:787–793. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pölcher M, Eckhardt M, Coch C, et al:
Sorafenib in combination with carboplatin and paclitaxel as
neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Cancer Chemother Pharmacol. 66:203–207. 2010.PubMed/NCBI
|
|
35
|
Eichbaum M, Mayer C, Eickhoff R, et al:
The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and
cyclophosphamide in patients with platinum-resistant recurrent,
pre-treated ovarian cancer. BMC Cancer. 11:4532011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Friedlander M, Hancock KC, Rischin D, et
al: A Phase II, open-label study evaluating pazopanib in patients
with recurrent ovarian cancer. Gynecol Oncol. 119:32–37. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Patel BB, He YA, Li XM, et al: Molecular
mechanisms of action of imatinib mesylate in human ovarian cancer:
a proteomic analysis. Cancer Genomics Proteomics. 5:137–149.
2008.PubMed/NCBI
|
|
38
|
Santen RJ, Brodie H, Simpson ER, Siiteri
PK and Brodie A: History of aromatase: saga of an important
biological mediator and therapeutic target. Endocr Rev. 30:343–375.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Juretzka M, Hensley ML, Tew W, et al: A
phase 2 trial of oral imatinib in patients with epithelial ovarian,
fallopian tube, or peritoneal carcinoma in second or greater
remission. Eur J Gynaecol Oncol. 29:568–572. 2008.PubMed/NCBI
|
|
40
|
Blank SV, Christos P, Curtin JP, et al:
Erlotinib added to carboplatin and paclitaxel as first-line
treatment of ovarian cancer: a phase II study based on surgical
reassessment. Gynecol Oncol. 119:451–456. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nimeiri HS, Oza AM, Morgan RJ, et al:
Efficacy and safety of bevacizumab plus erlotinib for patients with
recurrent ovarian, primary peritoneal, and fallopian tube cancer: a
trial of the Chicago, PMH, and California Phase II Consortia.
Gynecol Oncol. 110:49–55. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Garcia AA, Sill MW, Lankes HA, et al: A
phase II evaluation of lapatinib in the treatment of persistent or
recurrent epithelial ovarian or primary peritoneal carcinoma: A
gynecologic oncology group study. Gynecol Oncol. 124:569–574. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kimball KJ, Numnum TM, Kirby TO, et al: A
phase I study of lapatinib in combination with carboplatin in women
with platinum sensitive recurrent ovarian carcinoma. Gynecol Oncol.
111:95–101. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Weroha SJ, Oberg AL, Ziegler KL, et al:
Phase II trial of lapatinib and topotecan (LapTop) in patients with
platinum-refractory/resistant ovarian and primary peritoneal
carcinoma. Gynecol Oncol. 122:116–120. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Murphy M and Stordal B: Erlotinib or
gefitinib for the treatment of relapsed platinum pretreated
non-small cell lung cancer and ovarian cancer: a systematic review.
Drug Resist Updat. 14:177–190. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gnoni A, Marech I, Silvestris N, Vacca A
and Lorusso V: Dasatinib: an anti-tumour agent via Src inhibition.
Curr Drug Targets. 12:563–578. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Le XF, Mao W, Lu Z, Carter BZ and Bast RC
Jr: Dasatinib induces autophagic cell death in human ovarian
cancer. Cancer. 116:4980–4990. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Oza AM, Elit L, Tsao MS, et al: Phase II
study of temsirolimus in women with recurrent or metastatic
endometrial cancer: a trial of the NCIC Clinical Trials Group. J
Clin Oncol. 29:3278–3285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Behbakht K, Sill MW, Darcy KM, et al:
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation
of circulating tumor cells and tumor biomarkers in persistent and
recurrent epithelial ovarian and primary peritoneal malignancies: a
Gynecologic Oncology Group study. Gynecol Oncol. 123:19–26. 2011.
View Article : Google Scholar
|
|
50
|
Temkin SM, Yamada SD and Fleming GF: A
phase I study of weekly temsirolimus and topotecan in the treatment
of advanced and/or recurrent gynecologic malignancies. Gynecol
Oncol. 117:473–476. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kollmannsberger C, Hirte H, Siu LL, et al:
Temsirolimus in combination with carboplatin and paclitaxel in
patients with advanced solid tumors: a NCIC-CTG, phase I,
open-label dose-escalation study (IND 179). Ann Oncol. 23:238–244.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Janku F, Wheler JJ, Westin SN, et al:
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic
malignancies harboring PIK3CA mutations. J Clin Oncol. 30:777–782.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Radosa MP, Häfner N, Camara O, et al: Loss
of BRCA1 protein expression as indicator of the BRCAness phenotype
is associated with favorable overall survival after complete
resection of sporadic ovarian cancer. Int J Gynecol Cancer.
21:1399–1406. 2011. View Article : Google Scholar
|
|
54
|
Narod SA: BRCA mutations in the management
of breast cancer: the state of the art. Nat Rev Clin Oncol.
7:702–707. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Javle M and Curtin NJ: The potential for
poly (ADP-ribose) polymerase inhibitors in cancer therapy. Ther Adv
Med Oncol. 3:257–267. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lord CJ and Ashworth A: Targeted therapy
for cancer using PARP inhibitors. Curr Opin Pharmacol. 8:363–369.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Turner N, Tutt A and Ashworth A: Hallmarks
of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 4:814–819.
2004.
|
|
58
|
Penning TD: Small-molecule PARP modulators
- current status and future therapeutic potential. Curr Opin Drug
Discov Devel. 13:577–586. 2010.PubMed/NCBI
|
|
59
|
Fong PC, Yap TA, Boss DS, et al:
Poly(ADP)-ribose polymerase inhibition: frequent durable responses
in BRCA carrier ovarian cancer correlating with platinum-free
interval. J Clin Oncol. 28:2512–2519. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Gelmon KA, Tischkowitz M, Mackay H, et al:
Olaparib in patients with recurrent high-grade serous or poorly
differentiated ovarian carcinoma or triple-negative breast cancer:
a phase 2, multicentre, open-label, non-randomised study. Lancet
Oncol. 12:852–861. 2011. View Article : Google Scholar
|
|
61
|
Welch S, Hirte HW, Carey MS, et al: UCN-01
in combination with topotecan in patients with advanced recurrent
ovarian cancer: a study of the Princess Margaret Hospital Phase II
consortium. Gynecol Oncol. 106:305–310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Morgan MA, Parsels LA, Zhao LP, et al:
Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762
involves abrogation of the G2 checkpoint and inhibition of
homologous recombinational DNA repair. Cancer Res. 70:4972–4981.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Kajihara H, Yamada Y, Kanayama S, et al:
Clear cell carcinoma of the ovary: potential pathogenic mechanisms
(Review). Oncol Rep. 23:1193–1203. 2010.PubMed/NCBI
|
|
64
|
Yamada Y, Shigetomi H, Onogi A, et al:
Redox-active iron-induced oxidative stress in the pathogenesis of
clear cell carcinoma of the ovary. Int J Gynecol Cancer.
21:1200–1207. 2011.PubMed/NCBI
|
|
65
|
Smyth JF, Gourley C, Walker G, et al:
Antiestrogen therapy is active in selected ovarian cancer cases:
the use of letrozole in estrogen receptor-positive patients. Clin
Cancer Res. 13:3617–3622. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Fang F, Balch C, Schilder J, et al: A
phase 1 and pharmacodynamic study of decitabine in combination with
carboplatin in patients with recurrent, platinum-resistant,
epithelial ovarian cancer. Cancer. 116:4043–4053. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Modesitt SC, Sill M, Hoffman JS and Bender
DP; Gynecologic Oncology Group. A phase II study of vorinostat in
the treatment of persistent or recurrent epithelial ovarian or
primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gynecol Oncol. 109:182–186. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Tutt A, Robson M, Garber JE, et al: Oral
poly(ADP-ribose) polymerase inhibitor olaparib in patients with
BRCA1 or BRCA2 mutations and advanced breast cancer: a
proof-of-concept trial. Lancet. 376:235–244. 2010. View Article : Google Scholar
|
|
69
|
Itamochi H, Yoshida T, Walker CL, et al:
Novel mechanism of reduced proliferation in ovarian clear cell
carcinoma cells: cytoplasmic sequestration of CDK2 by p27. Gynecol
Oncol. 122:641–647. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Vance S, Liu E, Zhao L, et al: Selective
radiosensitization of p53 mutant pancreatic cancer cells by
combined inhibition of Chk1 and PARP1. Cell Cycle. 10:4321–4329.
2011. View Article : Google Scholar : PubMed/NCBI
|
